Precisetumor
Payments companies reported to CMS as associated with Precisetumor. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Precisetumor, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Precisetumor
These are the largest totals companies reported as associated with Precisetumor. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Devesh Pandya | Houston, TX | Hematology & Oncology | $50,665.68 |
| Sharyn Lewin | Teaneck, NJ | Gynecologic Oncology | $33,971.89 |
| Antonio Santillan-Gomez | San Antonio, TX | Gynecologic Oncology | $29,488.41 |
| Alfredo Santillan Gomez | San Antonio, TX | Surgical Oncology | $18,951.47 |
| Eric Manahan | Dalton, GA | Surgery | $14,243.47 |
| Catherine Appleton | Saint Louis, MO | Diagnostic Radiology | $11,212.50 |
| Kabeer Shah | Rochester, MN | Dermatopathology (Dermatology) | $11,175.00 |
| Ying Liu | New York, NY | Internal Medicine | $9,462.48 |
| Adam Brufsky | Pittsburgh, PA | $9,018.99 | |
| Michael Jones | Fond Du Lac, WI | Medical Oncology | $8,941.44 |
Prescribed Precisetumor?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.